Galectin Therapeutics
GALT
GALT
92 hedge funds and large institutions have $12.6M invested in Galectin Therapeutics in 2025 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 18 increasing their positions, 29 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more ownership
Funds ownership: →
less capital invested
Capital invested by funds: $ → $
less funds holding
Funds holding: →
38% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 29
71% less call options, than puts
Call options by funds: $757K | Put options by funds: $2.57M
Holders
92
Holding in Top 10
–
Calls
$757K
Puts
$2.57M
Top Buyers
| 1 | +$563K | |
| 2 | +$287K | |
| 3 | +$150K | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$67K |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
+$67K |
Top Sellers
| 1 | -$289K | |
| 2 | -$149K | |
| 3 | -$90.3K | |
| 4 |
Barclays
London,
United Kingdom
|
-$58.3K |
| 5 |
Morgan Stanley
New York
|
-$54.9K |
